- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of ticagrelor.
Atherothrombotic events post acute coronary syndromes: Prevention
Atherothrombotic events with history of myocardial infarction: Prevention
For prevention of atherothrombotic events in combination with aspirin in adults with:
Acute Coronary Syndromes (ACS).
History of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
Ticagrelor is indicated both for patients managed medically and those managed with percutaneous coronary intervention or a coronary artery by-pass graft.
Ticagrelor should be taken with a daily dose of 75mg to 150mg of aspirin, unless aspirin is specifically contraindicated.
Acute Coronary Syndromes
Loading dose: 180mg once only.
Maintenance dose: 90mg twice daily.
Treatment is recommended for up to 12 months, as experience beyond this time is limited.
History of myocardial infarction
60mg twice daily.
Treatment may be started without interruption as continuation therapy after the initial one year treatment with ticagrelor or other adenosine diphosphate (ADP) receptor inhibitor therapy in ACS patients with a high risk of an atherothrombotic event.
Treatment can be initiated up to 2 years from the MI, or within one year after stopping ADP receptor inhibitor treatment.
If a switch is needed, the first dose of ticagrelor should be administered 24 hours following the last dose of the other antiplatelet medication.
Additional Dosage Information
A patient who misses a dose of ticagrelor should take only one tablet (their next dose) at its scheduled time.
Children under 18 years
History of cerebrovascular haemorrhage
Severe hepatic impairment
Precautions and Warnings
Females of childbearing potential
Patients over 75 years
Predisposition to haemorrhage
Predisposition to syncope
Predisposition to trauma
Chronic obstructive pulmonary disease
History of asthma
History of gastrointestinal bleeding
History of hyperuricaemia
Moderate hepatic impairment
Moderate renal impairment
Non paced second/third degree AV block
Non-paced sinus node dysfunction
Uric acid nephropathy
Advise ability to drive/operate machinery may be affected by side effects
Consider clinical assessment if central sleep apnoea is suspected
Monitor renal function one month after initiation then periodically
Advise on the need to report unusual bleeding
Advise patient that omitting dose may increase CV risk
Advise patient to contact their doctor if dyspnoea rapidly worsens
May prolong bleeding time
May affect results of some laboratory tests
Discontinue 5 days prior to surgery when antiplatelet effect not required
Advise patient not to take NSAIDs unless advised by clinician
Advise patient not to take St John's wort concurrently
Advise patient grapefruit products may increase plasma level
Female: Ensure adequate contraception during treatment
Advise patient of risk of bleeding
Advise patient to inform physician/dentist of their use of this medication
Lapses in treatment or premature discontinuation of treatment should be avoided. Patients with acute coronary syndromes who discontinue antiplatelet therapy prematurely could be at increased risk of cardiovascular death or myocardial infarction due to underlying disease.
Creatinine levels may increase during treatment with ticagrelor. Renal function should be checked after one month and thereafter according to routine medical practice, paying special attention to patients over 75 years old, those with moderate-severe renal impairment or those receiving concomitant medical treatment with an angiotensin receptor blocker.
In healthy volunteers suffering bleeding due to excessive dosing, the use of platelet transfusions was not beneficial in reversing the antiplatelet action of ticagrelor. Therefore, if bleeding occurs, other supportive measures should be taken.
Antifibrinolytic therapy and/or recombinant factor VIIa may increase haemostasis. Treatment with ticagrelor may be resumed after the cause of bleeding has been identified and controlled.
Pregnancy and Lactation
Ticagrelor is contraindicated in pregnancy.
At the time of writing there is limited data on the use of ticagrelor in pregnancy. Studies in rats and rabbits have shown reproductive toxicity, with a slightly reduced body weight gain and reduced neonatal viability and birth weight with delayed growth. In female rats, ticagrelor at high dose showed an increased incidence of uterine tumours and hepatic adenomas (however this is considered by the manufacturer to be likely to be due to a rodent-specific mechanism). Minor developmental anomalies were seen in rats taking a maternally toxic dose. In rabbits, a slight delay in hepatic maturity and skeletal development was seen in foetuses from dams at high dose without showing maternal toxicity. Ticagrelor produced irregular cycles (mainly extended) in female rats but did not affect the overall fertility in male or female rats.
Ticagrelor is contraindicated in breastfeeding.
At the time of writing, there is limited published information concerning the use of ticagrelor during breastfeeding. Animal studies have shown that ticagrelor and its active metabolites are excreted into the breast milk of rats. It is unknown if ticagrelor is excreted into human breast milk. A risk to newborns or infants cannot be excluded.
Serum creatinine increased
Skin/soft tissue haemorrhage
Thrombotic thrombocytopenic purpura
Urinary tract bleeding
Effects on Laboratory Tests
Treatment with ticagrelor may cause false negative results in platelet function tests for heparin induced thrombocytopenia (HIT).
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: April 2016
Summary of Product Characteristics: Brilique 60mg film coated tablets. AstraZeneca UK Ltd. Revised November 2022.
Summary of Product Characteristics: Brilique 90mg film coated tablets. AstraZeneca UK Ltd. Revised November 2022.
Summary of Product Characteristics: Brilique 90mg Orodispersible Tablets. AstraZeneca UK Ltd. Revised November 2022.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 September 2022.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.